Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16-257.

被引：32

作者：

Galsky, Matt D.

Daneshmand, Siamak

Chan, Kevin G.

Dorff, Tanya B.

Cetnar, Jeremy Paul

Neil, Brock O.

D'souza, Anishka

Mamtani, Ronac

Kyriakopoulos, Christos

Garcia, Philip

Izadmehr, Sudeh

Yu, Menggang

Zhao, Qianqian

Mehrazin, Reza

Lewis, Sara C.

Sfakianos, John

Pal, Sumanta K.

机构：

[1] Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol, Tisch Canc Inst, New York, NY 10029 USA

[2] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA

[3] City Hope Natl Med Ctr, Duarte, CA USA

[4] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[5] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[6] USC Keck Sch Med, Div Oncol, Norris Comprehens Canc Ctr, Los Angeles, CA USA

[7] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[8] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[9] Icahn Sch Med Mt Sinai, Div Hematol Med Oncol, Tisch Canc Inst, New York, NY 10029 USA

[10] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[11] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA

[12] Univ Wisconsin Madison, Madison, WI USA

[13] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut, Duarte, CA USA

来源：

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.4503

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4503

引用

页数：3